Literature DB >> 3111795

Significance of the tuberculin test in the elderly.

E Dorken, S Grzybowski, E A Allen.   

Abstract

Nine hundred thirty-three persons over 65 years of age, residing in long-term or extended-care facilities in Vancouver, Canada, had tuberculin tests. In addition to PPD-tuberculin, 5 TU and 250 TU, we used PPD-Battey, Candida albicans, mumps, and Trichophyton antigens. Twenty-five percent reacted to 5 TU of tuberculin with reactions of 10 mm or more. There was a progressive, substantial loss of reactivity with advancing age. Reactions to PPD-Battey greater than to PPD-T 5 TU were infrequent, suggesting that atypical mycobacterial infections were uncommon and that positive reactions to PPD-T, 250 TU, were predominantly caused by infections with Mycobacterium tuberculosis. Based on the results of both 5 TU and 250 TU, the prevalence of tuberculous infection exceeded 60 percent. Waning of tuberculin sensitivity appears to be an integral part of the aging process. Testing with nonmycobacterial antigens used in this study shed no further light on the problem of anergy in the elderly, as the number of reactors was smaller than that obtained with PPD-tuberculin.

Entities:  

Mesh:

Year:  1987        PMID: 3111795     DOI: 10.1378/chest.92.2.237

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

1.  Evaluation of tuberculin skin testing in tuberculosis contacts in Victoria, Australia, 2005-2013.

Authors:  N Moyo; E L Tay; J T Denholm
Journal:  Public Health Action       Date:  2015-09-21

Review 2.  Immunosenescence revisited. Does it have any clinical significance?

Authors:  A J Voets; L R Tulner; G J Ligthart
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

3.  Standardization and Prevalence of the Booster Phenomenon: Evaluation Using a Two-Step Skin Test with 43 kDa Glycoprotein in Individuals from an Endemic Region of Paracoccidioidomycosis.

Authors:  Ana Paula C Marques; Sandra Maria V L Oliveira; Grazielli R Rezende; Dayane A Melo; Sonia M Fernandes-Fitts; Elenir Rose J C Pontes; Maria da Glória Bonecini-Almeida; Zoilo P Camargo; Rinaldo P Mendes; Anamaria M M Paniago
Journal:  Mycopathologia       Date:  2017-06-23       Impact factor: 2.574

4.  Essentials of tuberculosis control for the practising physician. Tuberculosis Committee, Canadian Thoracic Society.

Authors: 
Journal:  CMAJ       Date:  1994-05-15       Impact factor: 8.262

Review 5.  Age-related changes in the manifestations of tuberculosis. Implications for drug therapy.

Authors:  S Umeki
Journal:  Drugs Aging       Date:  1991 Nov-Dec       Impact factor: 3.923

Review 6.  [Pulmonary and pleural tuberculosis in the elderly].

Authors:  Gerhard Hoheisel; Anne Hagert-Winkler; Jörg Winkler; Thomas Kahn; Arne C Rodloff; Hubert Wirtz; Adrian Gillissen
Journal:  Med Klin (Munich)       Date:  2009-10-25

7.  Prevention of tuberculosis in older adults in the United States: obstacles and opportunities.

Authors:  Natasha S Hochberg; C Robert Horsburgh
Journal:  Clin Infect Dis       Date:  2013-01-29       Impact factor: 9.079

8.  Altered monocyte phenotypes but not impaired peripheral T cell immunity may explain susceptibility of the elderly to develop tuberculosis.

Authors:  Russell Ault; Varun Dwivedi; Elisha Koivisto; Jenna Nagy; Karin Miller; Kokila Nagendran; Indu Chalana; Xueliang Pan; Shu-Hua Wang; Joanne Turner
Journal:  Exp Gerontol       Date:  2018-07-03       Impact factor: 4.032

Review 9.  Does tuberculosis threaten our ageing populations?

Authors:  Rachel Byng-Maddick; Mahdad Noursadeghi
Journal:  BMC Infect Dis       Date:  2016-03-11       Impact factor: 3.090

10.  Local immune responses to tuberculin skin challenge in Mycobacterium bovis BCG-vaccinated baboons: a pilot study of younger and older animals.

Authors:  Julia M Scordo; Tucker J Piergallini; Nicole Reuter; Colwyn A Headley; Vida L Hodara; Olga Gonzalez; Luis D Giavedoni; James F Papin; Joanne Turner
Journal:  Immun Ageing       Date:  2021-04-07       Impact factor: 9.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.